New York State Common Retirement Fund Has $3.48 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

New York State Common Retirement Fund grew its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 37.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,866 shares of the biopharmaceutical company’s stock after acquiring an additional 19,673 shares during the period. New York State Common Retirement Fund owned 0.09% of Ultragenyx Pharmaceutical worth $3,484,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of RARE. Covestor Ltd raised its holdings in shares of Ultragenyx Pharmaceutical by 392.1% in the 3rd quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 596 shares during the period. UMB Bank n.a. raised its stake in Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 329 shares during the period. China Universal Asset Management Co. Ltd. lifted its position in shares of Ultragenyx Pharmaceutical by 97.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 903 shares during the last quarter. International Assets Investment Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 3,182.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,674 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 1,623 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 38.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,979 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 548 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Activity

In other news, insider John Richard Pinion sold 4,173 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the sale, the insider now directly owns 89,268 shares of the company’s stock, valued at $4,799,047.68. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 3,756 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $201,922.56. Following the completion of the transaction, the executive vice president now owns 67,340 shares of the company’s stock, valued at approximately $3,620,198.40. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider John Richard Pinion sold 4,173 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $224,340.48. Following the completion of the transaction, the insider now directly owns 89,268 shares in the company, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,116 shares of company stock worth $1,645,983. 6.80% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on RARE shares. Canaccord Genuity Group increased their price objective on shares of Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a “buy” rating in a research report on Wednesday, February 21st. JPMorgan Chase & Co. increased their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, March 18th. Robert W. Baird raised their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Wedbush decreased their target price on Ultragenyx Pharmaceutical from $48.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $107.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $88.00.

Ultragenyx Pharmaceutical Trading Down 1.0 %

Shares of Ultragenyx Pharmaceutical stock opened at $42.75 on Monday. The firm has a market capitalization of $3.55 billion, a P/E ratio of -5.32 and a beta of 0.68. The business’s fifty day simple moving average is $47.25 and its 200 day simple moving average is $44.22. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.31). The company had revenue of $108.83 million for the quarter, compared to analysts’ expectations of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 421.88% and a negative net margin of 138.58%. The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.33) EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.38 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.